IPSEN (OTCMKTS:IPSEY) Sees Strong Trading Volume - Here's What Happened

Key Points

• IPSEN shares saw a sharp jump in trading activity on Friday, with 10,866 shares traded, up 396% from the prior session. Despite the volume surge, the stock ended lower at $48.86 versus a previous close of $50.7044.
• Analyst sentiment is mixed, with UBS cutting IPSEN from strong-buy to hold, while Deutsche Bank reiterated a buy rating. MarketBeat says the stock currently has an average analyst rating of Hold.
• IPSEN remains focused on specialty biopharma, with core areas in oncology, neuroscience, and rare diseases. Its oncology portfolio includes treatments for prostate, renal, and hepatocellular cancers.

IPSEN (OTCMKTS:IPSEY - Get Free Report) shares saw an uptick in trading volume on Friday . 10,866 shares were traded during trading, an increase of 396% from the previous session's volume of 2,191 shares.The stock last traded at $48.86 and had previously closed at $50.7044.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on the company. UBS Group lowered IPSEN from a "strong-buy" rating to a "hold" rating in a research note on Thursday, January 8th. Deutsche Bank Aktiengesellschaft reiterated a "buy" rating on shares of IPSEN in a research report on Tuesday, April 14th. One analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of "Hold".

IPSEN Stock Down 3.6%

The stock has a fifty day moving average price of $47.02 and a 200-day moving average price of $40.97.

About IPSEN

Ipsen is a global biopharmaceutical company headquartered in Boulogne-Billancourt, France. Founded in 1929, the company focuses on specialty care areas including oncology, neuroscience and rare diseases. Ipsen develops, manufactures and commercializes innovative medicines that address critical unmet medical needs, offering a diverse portfolio of therapies for both adult and pediatric patient populations.

The company's oncology franchise includes treatments for prostate, renal and hepatocellular carcinomas, with key products such as Cabometyx (cabozantinib) and Decapeptyl (triptorelin).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.